by Anton Aulbers, TNO
One of the challenges of the pharma industry is the need for faster development and production of drug dosage forms for ever smaller target groups. TNO has built up a solid position and reputation in the field of 3D printing for the food industry.
Making use of this know-how base TNO is now together with partners, initiating innovations, in the pharma value chain, to unlock the potential of 3D Pharma printing as an enabling technology for cost effective small scale drug product manufacturing, dose personalization, multi-drug combinations and tailored release profiles.
In this way we aim to accelerate the translation of the increasingly available person specific health related data into truly personalized medicine.
What drives you?
What drives me is realizing valid solutions to real world problems. I am an engaged team player and I like to analyze complex problems, split them up in clear steps and identify surprising and creative solutions which can be implemented by and with partners.
Why should the delegate attend your presentation?
The possibilities for the combination of Personalized Medicine and 3D printing are exciting but still have a long way to go. Everybody in the field who is interested and wants to know more about the TNO state of the art is invited to take part in this journey.
What emerging technologies/trends do you see as having the greatest potential in the short and long run?
In the short run 3D Pharma printing can speed up the process of pharma R&D. In the long run as personalized diagnostics further develop it has the potential to enable truly personalized drug delivery.
What kind of impact do you expect them to have?
The impact of 3D Pharma printing can be on several levels.
For companies: Faster development and production of drug dosage forms for ever smaller target groups.
For consumers: Personalized treatment based upon individual health related data.
For society: Better health and a more effective and cost efficient health system.
What are the barriers that might stand in the way?
Barriers that have to be solved will be technological as well as logistical or regulatory.
I strongly believe that when you start working on it in the right place and with the right partners the hurdles can be solved along the way, building from a minimum viable product towards full system innovation.
Personalized Medicine is the future, 3D printing is part of the way to get there!
About Anton Aulbers
Anton has a background in Industrial Design Engineering. He has 30 years of experience in co-creating innovative multi-disciplinary technical solutions for and with customers in a wide range of domains, such as 3D printing.
He has been responsible for projects in the field of Equipment and Process development for Additive Manufacturing within TNO for the past 10 years.
As Senior Consultant 3D Pharma printing Anton now is taking the lead in tracking developments globally, defining the TNO roadmap for digital drug manufacturing, building strategic partnerships and developing the technology towards implementation in the market.
TNO is an independent research organization. We believe in the joint creation of economic and social value. We focus on transitions or changes in nine social themes. Innovation with purpose is what TNO stands for. We develop knowledge not for its own sake, but for practical application.
TNO connects people and knowledge to create innovations that boost the competitive strength of industry and the well-being of society in a sustainable way. In the field of 3D printing we focus on digital manufacturing processes and applications for the food and pharma sector, leading to new production models and products.